© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 14, 2021
Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
June 09, 2021
Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.
June 07, 2021
While survival rates were similar, acalabrutinib had lower rates of atrial fibrillation and other adverse events than ibrutinib for previously treated CLL.
Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.
June 03, 2021
Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma
May 31, 2021
A presentation at the recent 46th Annual Oncology Nursing Society’s Annual Meeting focused on ethical dilemmas facing oncology nurses and how clinicians are managing them.
May 06, 2021
Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.
April 22, 2021
According to the research, there are important components and factors missing from the scale commonly used to measure a clinician’s quality of life.
April 20, 2021
Improving patient care may be possible for institutions achieving Disease-Specific Care certifications with certified nurse specialists at the helm.
February 11, 2021
High response rates with novel eganelisib plus PD-1 inhibition is reported in patients with metastatic urothelial carcinoma, especially those with low PD-L1 expression.